Pillsbury advised Acer Therapeutics, a leading pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, on a definitive agreement for the purchase and sale of 2,920,306 shares of its common stock, including shares subject to pre-funded warrants.

The registered direct offering priced at-the-market, under Nasdaq rules. The gross proceeds from the offering are expected to be approximately $2.675 million, which Acer intends to utilize for general corporate purposes and working capital.

Click here to read the full company press release.

The Pillsbury deal team included partners Mike Hird and Christina Pearson and associates Chantele Karim and Ann Kim.